Cowen analyst Ritu Baral raised the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $149.00 (from $120.00) while ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Intercept Pharma (ICPT) Gives Back Most of NASH Trial GainsFebruary 20, 2019 11:29 AM Intercept Pharmaceuticals (ICPT) PT Raised to $248 at WedbushFebruary 19, 2019 1:57 PM Intercept Pharmaceuticals (ICPT) PT Raised to $175 at Oppenheimer; 'REGENERATE Top Line Sparks Joy'February 19, 2019 1:03 PM Buy Galmed Pharma (GLMD) On Galmed/OCA Combo - Cantor February 19, 2019 12:13 PM Two Key Intercept Pharma (ICPT) Takeaways From REGENERATE Results - RothFebruary 19, 2019 10:42 AM Intercept Pharmaceuticals (ICPT) Bullish View Reiterated at Needham & Company on Positive Positive Phase 3 REGENERATE NASH TrialFebruary 19, 2019 10:42 AM Intercept Pharma (ICPT) Estimates Raised At BairdFebruary 19, 2019 9:51 AM Increasing unusual put option volume: TNDM ICPTFebruary 19, 2019 9:42 AM Pre-Open Stock Movers 02/19: (ICPT) (NAVI) (VKTX) (ORBK) Higher; (WIN) (SLCA) (WTW) Lower (more...)February 19, 2019 8:56 AM Viking Therapeutics (VKTX) Trades Higher Following Positive Results From Intercept Pharma (ICPT)February 19, 2019 7:41 AM Intercept Pharma (ICPT) Announces Phase 3 REGENERATE Study in NASH Met Primary EndpointFebruary 19, 2019 7:03 AM Intercept Announces Positive Topline Results from Pivotal Phase 3 REGENERATE Study of Obeticholic Acid in Patients with Liver Fibrosis Due to NASHFebruary 19, 2019 7:01 AM